Canadian Generic Pharmaceutical Association (CGPA)
| Specific Topics of Lobbying Communications | Intended Outcomes | Associated Subject Matters |
|---|---|---|
|
Arranging a meeting between the CGPA and Ministerial Staff to provide a briefing on generic and biosimilars sectors and pan-Canadian Pharmaceutical Alliance agreement.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Continued support for Ministry of Health's policies regarding switching patients to biosimilar medicines from biologics
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Encouraging Support for the CGPA Blueprint for Sustainable Supply of Prescription Medicines for Canadians
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Expansion of reimbursement criteria by the Government of British Columbia for biosimilar products.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Invitation to Minister of Health to attend meeting with members of the CGPA, either at the annual members' meeting or at another time.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Policy and timing in respect of listing of sole-source and other generic drugs on the PharmaCare formulary where the price offered is higher than the Province's desired price. BC's position in respect of administration of pan-Canadian Pharmaceutical Association arrangements with the CGPA regarding generic drugs. Curtailing use of coupon cards for pharmaceutical products. Development of a regulatory pathway for biosimiars. Implementation of commitments made by British Columbia pursuant to its involvement with the pan-Canadian Pharmaceutical Alliance. Promoting greater utilization of generic prescription medicines. BC's position in respect of the National Pharmacare initiative. Accelerating time for listing of generic drugs after submission.
|
Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation, Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Requesting Pharmaceutical, Laboratory & Blood Services Division to provide firm written notice of price changes for reimbursement of generic drugs and listing of new generic drugs and earlier publication of changes to on-line formulary.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Signing Authority for Ministerial Orders to list generic products on the PharmaCare formulary
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity, Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
|
Health
|
|
Support for pan-Canadian Pharmaceutical Alliance agreement with Canadian Generic Pharmaceutical Association and for early negotiation of a renewal agreement.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|